SINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results

Bulletin Express

Mar 10

Hong Kong, 10 Mar 2026—SinoMab BioScience Limited (stock code: 03681, abbreviated as “SINOMAB BIO-B”) has announced that its Board of Directors will convene on 23 Mar 2026. The meeting’s primary agenda is to consider and approve the Group’s audited financial results for the fiscal year ended 31 Dec 2025 and to authorise their publication. Additional corporate matters may also be discussed.

The notice was issued by Dr. Shui On Leung, who currently serves as Executive Director, Chairman, and Chief Executive Officer. As of the announcement date, the Board comprises:

• Executive Director: Dr. Shui On Leung • Non-Executive Directors: Dr. Haigang Chen, Mr. Xun Dong, Ms. Xiaosu Wang, Dr. Jianmin Zhang • Independent Non-Executive Directors: Mr. George William Hunter Cautherley, Mr. Ping Cho Terence Hon, Dr. Chi Ming Lee, Ms. Chi Sau Giselle Lee, Mr. Nan Shen

Investors can expect the company’s FY2025 performance figures following Board approval and subsequent publication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1100642114"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100642114\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100642114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100642114","market":"hk","top_or_hot":-1,"title":"SINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results","media":"Bulletin Express","content":"<p>Hong Kong, 10 Mar 2026—SinoMab BioScience Limited (stock code: 03681, abbreviated as “SINOMAB BIO-B”) has announced that its Board of Directors will convene on 23 Mar 2026. The meeting’s primary agenda is to consider and approve the Group’s audited financial results for the fiscal year ended 31 Dec 2025 and to authorise their publication. Additional corporate matters may also be discussed.</p>\n<p>The notice was issued by Dr. Shui On Leung, who currently serves as Executive Director, Chairman, and Chief Executive Officer. As of the announcement date, the Board comprises:</p>\n<p>• Executive Director: Dr. Shui On Leung  \n• Non-Executive Directors: Dr. Haigang Chen, Mr. Xun Dong, Ms. Xiaosu Wang, Dr. Jianmin Zhang  \n• Independent Non-Executive Directors: Mr. George William Hunter Cautherley, Mr. Ping Cho Terence Hon, Dr. Chi Ming Lee, Ms. Chi Sau Giselle Lee, Mr. Nan Shen</p>\n<p>Investors can expect the company’s FY2025 performance figures following Board approval and subsequent publication.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 10 Mar 2026—SinoMab BioScience Limited (stock code: 03681, abbreviated as “SINOMAB BIO-B”) has announced that its Board of Directors will convene on 23 Mar 2026. The meeting’s primary agenda is to consider and approve the Group’s audited financial results for the fiscal year ended 31 Dec 2025 and to authorise their publication. Additional corporate matters may also be discussed.</p>\n<p>The notice was issued by Dr. Shui On Leung, who currently serves as Executive Director, Chairman, and Chief Executive Officer. As of the announcement date, the Board comprises:</p>\n<p>• Executive Director: Dr. Shui On Leung  \n• Non-Executive Directors: Dr. Haigang Chen, Mr. Xun Dong, Ms. Xiaosu Wang, Dr. Jianmin Zhang  \n• Independent Non-Executive Directors: Mr. George William Hunter Cautherley, Mr. Ping Cho Terence Hon, Dr. Chi Ming Lee, Ms. Chi Sau Giselle Lee, Mr. Nan Shen</p>\n<p>Investors can expect the company’s FY2025 performance figures following Board approval and subsequent publication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03681","symbol_name":"中国抗体-B","start_time":0,"source_url":"","article_id":"1100642114","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100642114","pubTimestamp":1773144163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 10 Mar 2026—SinoMab BioScience Limited (stock code: 03681, abbreviated as “SINOMAB BIO-B”) has announced that its Board of Directors will convene on 23 Mar 2026. The meeting’s primary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03681":"中国抗体-B"},"translate_title":"SINOMAB BIO-B(03681.HK)定于2026年3月23日召开董事会批准2025财年末期业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":1},"content_text":"Hong Kong, 10 Mar 2026—SinoMab BioScience Limited (stock code: 03681, abbreviated as “SINOMAB BIO-B”) has announced that its Board of Directors will convene on 23 Mar 2026. The meeting’s primary agenda is to consider and approve the Group’s audited financial results for the fiscal year ended 31 Dec 2025 and to authorise their publication. Additional corporate matters may also be discussed.\nThe notice was issued by Dr. Shui On Leung, who currently serves as Executive Director, Chairman, and Chief Executive Officer. As of the announcement date, the Board comprises:\n• Executive Director: Dr. Shui On Leung  \n• Non-Executive Directors: Dr. Haigang Chen, Mr. Xun Dong, Ms. Xiaosu Wang, Dr. Jianmin Zhang  \n• Independent Non-Executive Directors: Mr. George William Hunter Cautherley, Mr. Ping Cho Terence Hon, Dr. Chi Ming Lee, Ms. Chi Sau Giselle Lee, Mr. Nan Shen\nInvestors can expect the company’s FY2025 performance figures following Board approval and subsequent publication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}